Clinical trial
Efficacy and Safety of Oral Febuxostat in Participants With Gout
NCT00430248 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00430248 |
|---|---|
| Title | Efficacy and Safety of Oral Febuxostat in Participants With Gout |
| Official title | A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout. |
| Acronym | CONFIRMS |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gout |
| Intervention type | Drug |
| Interventions | Febuxostat, Allopurinol |
| Enrollment | 2,269 |
| Start date | Feb 1, 2007 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Feb 1, 2007 |
| Last update posted | Feb 2, 2012 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: